Plasmodium falciparum surface antigen 230 domain 1 (Pfs230D1)

Plasmodium falciparum surface antigen 230 domain 1 (Pfs230D1) is a key surface antigen expressed during the sexual stages of the malaria parasite, specifically on gametocytes and gametes [1, 14]. It belongs to the 6-cysteine (6-cys) protein family and is essential for gamete fertilization and the formation of exflagellation centers through interaction with host erythrocytes [9, 11, 14]. Pfs230D1 is the primary target of leading transmission-blocking vaccines (TBVs) aimed at interrupting the malaria life cycle within the Anopheles mosquito [2, 4]. These vaccines work by inducing host antibodies that, upon ingestion by a mosquito during a blood meal, bind to the parasite surface and prevent its development into oocysts, often through complement-mediated lysis [5, 13, 16]. Clinical candidates such as Pfs230D1-EPA, formulated with adjuvants like AS01 or Matrix-M, have demonstrated safety and the ability to elicit durable functional immunity in both malaria-naive and malaria-experienced populations [10, 17, 18]. Although Pfs230D1-targeted interventions do not provide direct clinical protection to the individual, they are considered a cornerstone for malaria elimination and eradication strategies by reducing the transmission of the parasite across communities [7, 12].

Other names

Pfs230 domain 1Pfs230D1MPfs230D1+6-cys protein Pfs230Plasmodium falciparum sexual stage 230 kDa protein

Induction of transmission-blocking antibodies that bind to the gamete surface and inhibit fertilization or development in the mosquito midgut, often through complement-mediated lysis.